Solid Biosciences Inc

+0.01 (+0.50%)
Products, Regulatory

Solid Biosciences Reports 1.5-Year Data From Patients In Ongoing IGNITE DMD Phase I/II Clinical Trial Of SGT-001

Published: 09/23/2021 10:57 GMT
Solid Biosciences Inc (SLDB) - Solid Biosciences Reports 1.5-year Data From Patients in the Ongoing Ignite Dmd Phase I/ii Clinical Trial of Sgt-001.
Solid Biosciences Inc - Data Support Continued Functional Benefit 1.5 Years Post Treatment Compared With Natural History Data.
Solid Biosciences Inc - Patient Reported Outcomes Showed Sustained Improvements at 1.5 Years Compared to Patient Baseline and Natural History Data.
Solid Biosciences Inc - No New Drug-related Safety Findings for a Period of Up to 3.5 Years.